SwiftPharma develops plant-based biomanufacturing technologies for producing animal-free proteins, vaccines, antibodies and biosimilars. The company uses plants as miniature bioreactors to generate recombinant proteins for applications in healthcare, bioterrorism countermeasures and agriculture. Its pipeline and CDMO services cover areas such as antiviral candidates like griffithsin, coronavirus and influenza vaccine concepts, cancer therapeutics and antidotes to toxins including ricin. SwiftPharma designs processes aimed at scalable, flexible and cost-conscious production compared with conventional cell-culture and animal-derived systems. Partnerships with pharma, biotech and research organizations support contract development, process optimization and small to mid-scale manufacturing of plant-made biologics. The organization also contributes to European biotechnology advocacy focused on sustainable and animal-free production methods.
